Skip to main content
OpenTrials
Completed

NCT Number: NCT02679846

Safety of Antiepileptic Withdrawal in Long Term Video-EEG Monitoring

SAVE is a stratified cluster-randomised controlled, parallel group, open-label trial, with Epileptic Monitoring Unit (EMU) as the units of randomisation and patients as the unit of analysis.

The focus of research is the management of AntiEpileptic Drugs (AEDs) withdrawal during long term Video EEG (VEEG) monitoring in patients with drug resistant seizures. This non-standardised medical practice, which aims at promoting the occurrence of seizures during the time limit of the monitoring period, exposes patients to significant risks which should be minimised by harmonisation of practice and a standardised protocol of AEDs withdrawal.

SAVE will assess the impact of a standardised protocol of AEDs withdrawal during long-term VEEG monitoring on the frequency of seizure-related serious adverse events occurring during these monitorings and on the ability to obtain VEEG recording of seizures within appropriate time limits.

10 of the 22 EMUs will be randomised to the group where the standardised protocol of AEDs withdrawal will be used systematically, while the other ten EMUs will continue their current non-standardised practice of AEDs withdrawal, and will serve as a control group.

The setting of the study will include a 6 months evaluation phase, prior to randomisation, during which the organisational characteristics, baseline EMUs' activity, current management of AEDs withdrawal, and rate of Serious Adverse Events (SAEs) of each participating center will be evaluated.

The standardised study protocol of AEDs withdrawal has been defined on the basis of a systematic review of all relevant publications in the field.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Nord, Amiens, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female suffering from drug-resistant epilepsy
  • Age ≥ 6 years old
  • Inpatient in one of the participating EMUs for recording seizure during long-term VEEG monitoring (≥ 48 hours)
  • Patient who gave its written informed consent to participate to the study, or for children, whose minimum one of parents had given its written informed consent

Exclusion criteria

  • Age < 6 years old
  • Inpatient in one of the participating EMUs for performing short-term VEEG monitoring (<48 hours)
  • Pregnant or breastfeeding woman

Treatment and study plan

Standardized protocol

Other

The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients

Primary outcomes

  1. Proportion of patients who develop seizure-related serious adverse events during long-term VEEG monitoring

    Time frame: from date of inclusion until end of study (maximum 36 days)

    Proportion of patients who develop seizure-related serious adverse events during long-term VEEG monitoring, defined as the occurrence of one or more of the following events:

    • Convulsive or non-convulsive status epilepticus
    • 4-hour seizure cluster (≥ 3 seizures / 4 hours)
    • secondarily generalised seizure unusual for the patient (≤ 1/year)
    • vertebral compression
    • other fracture (including broken tooth)
    • post-ictal psychosis
    • post-ictal aspiration pneumonia
    • cardio-respiratory arrest
    • Any other seizure-related serious injury or adverse events

Secondary outcomes

  1. Proportion of patients who develop each of the above seizure-related SAEs during long-term VEEG monitoring

    Time frame: from date of inclusion until end of study (maximum 36 days)

  2. Proportion of patients who develop SAEs unrelated to the occurrence of a seizure, during long-term VEEG monitoring

    Time frame: from date of inclusion until end of study (maximum 36 days)

  3. Proportion of patients who develop adverse events, including serious and non-serious adverse events, during long-term VEEG monitoring

    Time frame: from date of inclusion until end of study (maximum 36 days)

  4. Delay between onset of monitoring and VEEG recording of the first seizure (in hours)

    Time frame: from date of inclusion until the first seizure (maximum 21 days)

  5. Proportion of patients in whom at least one seizure will be recorded during the VEEG monitoring

    Time frame: from date of inclusion until the end of monitoring (maximum 21 days)

  6. Proportion of patients in whom the duration of VEEG monitoring will extend beyond its initially scheduled time limits

    Time frame: from date of inclusion until the end of monitoring (maximum 21 days)

  7. Duration of VEEG

    Time frame: from date of inclusion until the end of monitoring (maximum 21 days)

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: SAVE

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Feb 10, 2016
Registry last updated
Jan 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.